机构:[1]Heilongjiang Univ Chinese Med, Natl Chinmed Res Ctr, Dept Pharmaceut Anal,Metab Lab, State key Lab Integrat & Innovat Class Formula & M, Heping Rd 24, Harbin 150040, Peoples R China[2]Macau Univ Sci & Technol, State Key Lab Qual Res Chinese Med, Ave Wai Long, Taipa, Macao, Peoples R China[3]Guangzhou Univ Chinese Med, Affiliated Hosp 2, State Key Lab Dampness Syndrome, Dade Rd 111, Guangzhou, Peoples R China大德路总院广东省中医院
Albeit remarkable achievements in anti-cancer endeavors, the prevention and treatment of cancer remain unresolved challenges. Hence, there is an urgent need to explore new and efficacious natural compounds with potential anti-cancer therapeutic agents. One such group of compounds is alisols, tetracyclic triterpene alcohols extracted from alisma orientale. Alisols play a significant role in cancer therapy as they can suppress cancer cell proliferation and migration by regulating signaling pathways such as mTOR, Bax/Bcl-2, CHOP, caspase, NF-kB and IRE1. Pharmacokinetic studies showed that alisols can be absorbed entirely, rapidly, and evenly distributed in vivo. Moreover, alisols are low in toxicity and relatively safe to take. Remarkably, each alisol can be converted into many compounds with different pathways to their anti-cancer effects in the body. Thus, alisols are regarded as promising anti-cancer agents with minimal side effects and low drug resistance. This review will examine and discuss alisols' anti-cancer molecular mechanism, pharmacokinetics and metabolism. Based on a comprehensive analysis of nearly 20 years of research, we evaluate the therapeutic potential of alisols for various types of cancer and offer insights and strategies for developing new cancer treatments.
基金:
This work was supported by Key Projects of the National Natural Science Foundation (81830110), Natural Science Foundation of Henan Province (H2022106061), and National Major New Drug Innovation Project (2015ZX09101043-011).
语种:
外文
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2022]版:
大类|2 区医学
小类|1 区药学2 区医学:研究与实验
最新[2025]版:
大类|2 区医学
小类|2 区医学:研究与实验2 区药学
JCR分区:
出版当年[2021]版:
Q1MEDICINE, RESEARCH & EXPERIMENTALQ1PHARMACOLOGY & PHARMACY
最新[2023]版:
Q1MEDICINE, RESEARCH & EXPERIMENTALQ1PHARMACOLOGY & PHARMACY
第一作者机构:[1]Heilongjiang Univ Chinese Med, Natl Chinmed Res Ctr, Dept Pharmaceut Anal,Metab Lab, State key Lab Integrat & Innovat Class Formula & M, Heping Rd 24, Harbin 150040, Peoples R China
通讯作者:
通讯机构:[1]Heilongjiang Univ Chinese Med, Natl Chinmed Res Ctr, Dept Pharmaceut Anal,Metab Lab, State key Lab Integrat & Innovat Class Formula & M, Heping Rd 24, Harbin 150040, Peoples R China[2]Macau Univ Sci & Technol, State Key Lab Qual Res Chinese Med, Ave Wai Long, Taipa, Macao, Peoples R China[3]Guangzhou Univ Chinese Med, Affiliated Hosp 2, State Key Lab Dampness Syndrome, Dade Rd 111, Guangzhou, Peoples R China
推荐引用方式(GB/T 7714):
Wu Yinqi,Wang Xijun,Yang Le,et al.Potential of alisols as cancer therapeutic agents: Investigating molecular mechanisms, pharmacokinetics and metabolism[J].BIOMEDICINE & PHARMACOTHERAPY.2023,168:doi:10.1016/j.biopha.2023.115722.
APA:
Wu, Yinqi,Wang, Xijun,Yang, Le,Kang, Shuyu,Yan, Guangli...&Sun, Hui.(2023).Potential of alisols as cancer therapeutic agents: Investigating molecular mechanisms, pharmacokinetics and metabolism.BIOMEDICINE & PHARMACOTHERAPY,168,
MLA:
Wu, Yinqi,et al."Potential of alisols as cancer therapeutic agents: Investigating molecular mechanisms, pharmacokinetics and metabolism".BIOMEDICINE & PHARMACOTHERAPY 168.(2023)